HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company), a novel bioelectric medicine company bringing to market its proprietary CellFX™ System, announced today that Sandra (“Sandy”) Gardiner will be joining as the Company’s Executive Vice President and Chief Financial Officer effective November 18, 2019. Sandy will join Pulse Biosciences with 30 years of financial, operational and strategic leadership experience in the life sciences, including 20 years in medical devices. Brian Dow has elected to resign as Senior Vice President and Chief Financial Officer to pursue other interests, he will continue as CFO until November 18, 2019 and will continue with



This content is restricted to site members. If you are an existing user, please log in. New users may register too.